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Background: Human Papillomavirus (HPV) infection is a serious problem for human immunodeficiency virus
(HIV)-infected women, increases their risk of cervical lesions and cancer. In cervical carcinogenesis, mutations in the
p53 gene occur most frequently within exons 5–8. To our knowledge, no previous studies have analyzed mutations
in exons 5–8 of the p53 gene in HIV- and HPV-infected women. In our study, we verified these mutations in
women with and without cervical abnormalities.
Findings: The study included 160 women, divided into three groups: (1) 83 HPV- and HIV-infected women (HIV
group); (2) 37 HPV-infected/HIV-uninfected (control group); and (3) 40 normal cytology/DNA-HPV negative/HIV-
uninfected women (negative control p53 reactions). HPV-DNA was detected using polymerase chain reaction (PCR)
and genotyping by PCR-restriction fragment length polymorphism analysis. Using primers for exons 5–8, the
mutation of the p53 gene was verified by PCR-single strand conformational polymorphism. The total mutation of
the p53 gene in exons 5–8 was not significantly associated with the HIV and control groups. The mutations in exon
7 were the highest in the HIV group (43.8%) and in exon 6 in the control group (57.2%) (p = 0.0793) suggesting a
tendency toward differential mutation in exon 7 in the HIV group.
Conclusions: Our study provides preliminary evidence that the mutation in exon 7 might be an important
differentiating factor for cervical carcinogenesis in HIV-infected women. This aspect deserves an additional
cross-sectional and longitudinal study using a larger sample size with a higher number of High-grade squamous
intraephitelial lesion (HSIL) to observe the evolution of cervical lesions.
Keywords: HIV, HPV, Cervical lesions, p53 gene, Mutations, Exons 5–8Findings
Human Papillomavirus (HPV) infection is a particularly
difficult problem for human immunodeficiency virus
(HIV)-infected women because they are more vulnerable
to infection and less likely to clear the virus, which in-
creases their risk of developing cervical lesions and cancer
[1]. Specifically, there are differences in the prevalence,
incidence, progression and regression of HPV-related cer-
vical diseases in HIV-infected women compared to HIV-
uninfected women. Moreover, in HIV-infected women,* Correspondence: melconsolaro@gmail.com
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reproduction in any medium, provided the orcervical cancer (CC) responds poorly to recommended
therapies, behaves more aggressively, and in cases of recur-
rence, has a poorer prognosis [1,2]. The severe impact of
HIV in relation to CC was demonstrated in a study that
showed that HIV-positive women had an almost five fold
greater chance of developing precancerous lesions than did
HIV-uninfected women [3].
In cervical carcinogenesis, the integration of high-risk
HPV (HR-HPV) into host-cell chromosomes is followed
by the binding of HPV E6 and E7 oncoproteins with
tumor suppressor proteins p53 and pRb, respectively.
This process results in impaired tumor suppressor gene
function, involving DNA repair, decreased apoptosis,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eventual cell immortalization [4].
The p53 tumor suppressor gene specifically inhibits
cell cycle progression and promotes DNA repair and/or
apoptosis; its inactivation is correlated with a critical
step in the development of many human cancers. Inacti-
vation may result from a number of events, including
mutation of the p53 gene (with or without associated al-
lelic deletions) and binding of the p53 gene to cellular or
viral proteins, such as the HPV E6 oncoprotein [5]. p53
mutations are mostly missense in nature and are located
predominantly within the DNA-binding domain, where
a single mutation is sufficient to cause loss of normal
p53 function [6]. Studies on the association between CC
and the loss of p53 function have yielded conflicting re-
sults [5,7,8].
Mutations in the p53 gene occur most frequently within
exons 5–8, which is the highly conserved DNA binding
domain region [9]. Studies on p53 that included all exons
have suggested that mutations outside exons 5–8 are rare
in tumors [10]. However, most studies on the involvement
of the p53 gene in cervical carcinogenesis are related to its
protein expression by immunohisto/cytochemical or poly-
morphism in condon-72 [5,7]. To our knowledge, no pre-
vious studies have analyzed the mutations in exons 5–8 of
the p53 gene in HIV- and HPV-infected women. In our
study, we verified these mutations in women with and
without cervical abnormalities.
The study included cervical samples of 160 women who
were divided into three groups: (1) 83 HPV- and HIV-
infected (HIV group); (2) 37 HPV-infected/HIV-unin-
fected (control group); and (3) 40 cervical samples from
women with normal cytology/DNA-HPV negative/HIV-
uninfected that were only used as a negative control for
the mutation of the p53 gene exons (negative control p53
reactions). The women included in the study were
enrolled in the Specialized Assistance Service (SAE) for
sexually transmitted diseases (STD)/AIDS in Maringá,
Brazil, between April 1, 2011, and October 30, 2011. In
these samples, HPV-DNA was previously detected (data
not shown) in the Clinical Cytology Laboratory at the
State University of Maringá (UEM), Brazil, and stored
at −80°C. Stored samples from HIV-infected and HIV-
uninfected women, both with and without cervical lesions,
were included in the study. The samples for 1 and 2
groups were also HPV-DNA positive.
Cervical and endocervical samples were collected
using a cytobrush and an Ayre’s spatula, transferred to
1.5 ml tubes with 1.0 ml of sterile 0.9% NaCl solution,
and stored at −80°C. Genomic DNA was extracted using
the AxyPrep™ Body Fluid Viral DNA/RNA Miniprep Kit
(AP-MN-Bf-VNA-50, Axygen, CA, USA) according to
the manufacturer’s instructions. The quality and quantity
of purified DNA were measured by spectrophotometry.HPV polymerase chain reaction (PCR) amplification for
HPV was conducted using primers MY09 (5′CGTCCM
AARGGAWACTGATC-3′) and MY11 (5′-GCMCAG
GGWCATAAYAATGG-3′); co-amplification of the hu-
man β-globin gene was performed as an internal control
using primers GH20 (5′-GAAGAGCCAAGGACAGG
TAC-3′) and PC04 (5′-CAACTTCATCCACGTTCACC-
3′) under the same conditions as for the HPV-PCR [11].
The cytological smears were prepared with a portion of
the collected material and were reported according to the
Bethesda System [12]: normal, without altered cells; atyp-
ical squamous cells of undetermined significance, cannot
exclude high-grade squamous intraepithelial lesion (ASC-
H); low-grade squamous intraepithelial lesion (LSIL); or
high-grade squamous intraepithelial lesion (HSIL). Cases
with a cytological diagnosis of HSIL were confirmed by
histopathology.
For HPV genotyping of selected samples, a new HPV-
PCR amplification was performed, which was followed by
PCR-Restriction Fragment Length Polymorphism (PCR-
RFLP) analysis using HpyCH4V [13]. The mutations of the
p53 gene was verified by PCR-Single Strand Conform-
ational Polymorphism (PCR-SSCP), which detects molecu-
lar changes in single-stranded DNA that cause changes in
electrophoretic mobility [8]. The following primers were
used: exon 5 (5′-TGTTCACTTGTGCCCTGACT-3′) /
(5′-AGC AAT CAG TGA GGA ATC AG-3′), 310 bp;
exon 6 (5′-TGGTTGCCCAGGGTCCCCAG-3′) / (5′-
TGGAGGGCCACTGACAACCA–3′), 223 bp; exon 7 (5′-
CTTGCCACAGGTCTCCCCAA-3′) / (5′-AGGGGTCA
GCGGCAAGCAGA-3′), 248 bp; and exon 8 (5′-TTGGG
AGTAGATGGAGCCT-3′) / (5′-AGAGGCAAGGAAAG
GTGATA-3′), 213 bp. This is a simple technique which
allows the identification of samples with type missense
mutation, as well as correlation with the expression of mu-
tated p53 [14]. The women signed a consent form, and this
study was approved by the Committee for Ethics in
Research Involving Humans at the State University of
Maringá (UEM)/Paraná, Brazil (No. 085/2011).
The statistical analysis was performed using STATISTICA
8.0 software, and all of the variables were expressed as ab-
solute and relative frequencies. The rates of p53 exon mu-
tations in the groups of women were compared using a
non-parametric Z test. A p value < 0.05 was considered
statistically significant.
On average, the HIV group was older than the control
group (40.9 ± 11.23 vs 35.7 ± 10.57 years old; p = 0.0254).
The majority of the HIV group showed excellent control
of the HIV infection, as determined by the correct use
of highly active antiretroviral therapy (HAART) (79.2%),
current CD4+ T lymphocyte count > 350 cells/mm3
(73.6%) and current viral load < minimum limit (58.4%)
or between the minimum limit and 100 copies/mL
(38.8%).
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HPV-51 and HPV-16 (n = 11/83, 13.5% each). Of these
samples, a p53 mutation occurred in only 1 sample of
HPV-16 (9.1%) and in 6 samples of HPV-51 (54.5%). For
the control group, HPV-16 (n = 6/37, 16.2%) and HPV-
66 (n = 5/37, 13.5%) were the most common, but the
p53 mutation was observed in only 1 sample each
(16.7% and 20.0%, respectively). HPV-58 was detected in
2 samples, and the mutation occurred in these 2 samples
(100%). In regards to the cytological findings, the HIV
group showed the following: 70 normal, 2 ASC-H, 10
LSIL and 1 HSIL. The findings in the control group
were as follows: 21 normal, 6 ASC-H, 9 LSIL and 1
HSIL (Table 1).
Figure 1(a) shows a mutation in exon 6 as an example
of abnormal bands of the p53 gene. In total, 19.3% of the
HIV group and 18.9% of the control group (p = 0.4896)
showed mutations in the p53 gene and all had HR-HPV.
As previously described, no mutations occurred in any
of the negative control p53 reactions [15] which is base-
line condition this population. A mutation in exon 7
alone or together with a mutation in exon 6 was the
highest in the HIV group (43.8%), and a mutation in
exon 6 was highest in the control group (57.2%) (p =
0.0793) (Figure 1b). However, because the p value was
close to being statistically significant, these data may
suggest a tendency toward mutations in exon 7 in the
HIV group.
In the HIV group, a mutation in exon 7 occurred
at the highest frequency in normal cytology (31.3%)
followed by LSIL and HSIL (6.3% for both). For the con-
trol group, a mutation in exon 6 was most common in
both normal cytology and LSIL (28.6% each) (Table 1).
There was no difference in mutation rates in normal cy-
tology or lesions in both groups (p = 0.4956 and 0.3303,
respectively; Table 1).
These findings suggested that the HPV infection ap-
pears to lead to a mutation in the p53 gene in different
exons in HIV-infected and HIV-uninfected women, i.e.,
mainly in exons 7 and 6, respectively. A point mutationTable 1 Distribution of mutations in the p53 gene in HIV grou
Cytologic
findings
Total samples p53 mutation
N % N %
Normal Cytology 70 84.3 12 17.1
ASC-H 2 2.4 1 50.0
LSIL 10 12.1 2 20.0
HSIL 1 12 1 100.0
TOTAL 83 100.0 16 19.3
HPV, human papillomavirus; HIV, human immunodeficiency virus; cytologic findings
undetermined significance, cannot exclude high-grade squamous intraepithelial les
squamous intraepithelial lesion (HSIL).
*p < 0.05 was considered significant.at the splice donor site at the 3′ end of exon 7 of the hu-
man p53 gene results in the retention of the intron 7 se-
quence in the mRNA, thereby inactivating the p53
protein [16].
We also showed that the total mutation in p53 gene
exons 5–8 was not significantly associated with the HIV
and control groups, and in women of both groups with
normal cytology or different grades of cervical abnor-
malities, similar to those described for p53 gene condon
72 polymorphism [7] and p53 gene immunoexpression
[5] in HIV-uninfected women. Interestingly, the samples
from the HIV group with HPV-51 showed the highest
rates of mutations in the p53 gene which deserves fur-
ther studies. Overall, higher rates of cervical HPV infec-
tion and CC can be partly related to a more specific
mutated exon in HIV-infected patients.
Through its effect on CD4 cells and regulation of im-
mune responses to a variety of antigens, HIV infection
may attenuate the systemic immune response to HPV. It
is speculated that if there is a low number of circulating
HPV-specific memory cells, then HPV-specific immunity
may be particularly vulnerable to the effects of HIV. Pos-
sible due to this HIV-infected women are more vulner-
able to infection and less likely to clear the virus, which
increases their risk of developing cervical lesions and
cancer [1]. According to this hypothesis, HPV-specific
immunity may not recover fully after immune response
is restored, which may explain the relatively limited
beneficial effect of HAART on HPV cervical infection
and CC [17].Conclusions
In conclusion, we acknowledge that we did not study
women with CC, and we studied few women with HSIL.
However, our study cannot exclude the possibility that
the mutations in the p53 gene may act at later stages of
carcinogenesis. Nevertheless, we believe that our study
provides preliminary evidence that the mutation in exon
7 might be an important differentiating factor forp and control group
Total samples p53 mutation
*p
N % N %
21 56.8 4 19.0 0.4956
6 16.2 - -
9 24.3 3 33.3 0.3303
1 2.7 - -
37 100.0 7 18.9 0.4896
(according to Bethesda System 2001): atypical squamous cells of




Figure 1 Mutation in exon 6 of the p53 gene in the HIV group compared with the control group. Panel a: Electrophoretic analysis of
cervical p53 gene mutations using PCR-Single Strand Conformational Polymorphism (PCR-SSCP) in an 8% polyacrylamide gel stained with
ethidium bromide. Samples A1-A3, negative for p53 gene mutations; A4, positive for p53 gene mutation (arrow); C, negative control p53
reactions; M, 25 bp molecular weight marker. Panel b: The frequency of mutations in p53 exons 5 to 8 in both groups. Exon 7 and exon 6 were
the most mutated exons examined in the HIV group and in the control group, respectively.
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pect deserves an additional cross-sectional and longitudinal
study using a larger sample size with a higher number of
HSIL to observe the evolution of cervical lesions.
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